20
Participants
Start Date
September 1, 2024
Primary Completion Date
July 1, 2026
Study Completion Date
July 1, 2028
Selinexor
Selinexor is an oral therapy that is FDA approved for multiple myeloma and diffuse large B-cell lymphoma that have returned after prior therapy. Side effects like nausea, vomiting, and fatigue can affect how long a patient is able to continue taking Selinexor, which could mean that treatment might stop sooner.
Durham VA Medical Center, Durham
Lead Sponsor
Collaborators (1)
Duke University
OTHER
Durham VA Medical Center
FED